Alerta

COMPOSITION COMPRISING NICOTINAMIDE, NICOTINAMIDE PRECURSORS, NICOTINAMIDE METABOLITES OR COMBINATIONS THEREOF FOR PREVENTING OR REDUCING ONE OR MORE POST-ACUTE SYMPTOMS OF INFECTIOUS DISEASES

Resumen de: US2025213549A1

A composition comprising an active substance selected from nicotinamide; nicotinic acid; nicotinic acid esters; tryptophan; a tryptophan dipeptide; nicotinamide adenine dinucleotide (NAD); nicotinamide adenine dinucleotide phosphate (NADP); an intermediate in the biosynthesis of NAD or NADP selected from the group consisting of N-formylkynurenine, L-kynurenine, 3-hydroxy-L-kynurenine, 3-hydroxyanthranilate, 2-amino-3-carboxymuconate semialdehyde, quinolinate, nicotinic acid mononucleotide (beta-nicotinate D-ribonucleotide), and nicotinic acid adenine dinucleotide; nicotinamide riboside; nicotinamide mononucleotide; 1-methylnicotinamide (N-methylnicotinamide); or a combination thereof, for use for preventing and/or reducing one or more post-acute symptoms of an infection, wherein the composition is formulated to partly or completely release the active substance(s), preferably nicotinamide, for topical supplementation or efficacy in the lower small intestine and/or the colon, wherein preferably the pathogen is SARS-CoV-2 and/or the post-acute symptoms are PCS

Rolling Sensor Systems for Detecting Analytes and Diagnostic Methods Related Thereto

Resumen de: US2025216390A1

This disclosure relates to sensing the movement of DNA rolling motors comprising microparticles or rods on transduction material in the presence of viruses, microbes, or other analytes for diagnostic testing. In certain embodiments, the presence of viral particles, other target microbial biomolecules, or analytes stall the motor by specifically binding to aptamers crosslinking the analytes to the particles, rods, or surface of the transduction material. It is contemplated that microparticles or other rolling motors move along a surface whereby an aptamer targets an analyte, e.g., viral SARS-CoV-2, and acts to inhibit, reduce, or restrict the speed, acceleration, or area of movement on the surface indicating the presence of the analyte in the sample.

PHARMACEUTICAL COMPOSITIONS

Resumen de: WO2025141542A1

A method of treating or reducing symptoms of coronavirus disease includes administering a therapeutically effective amount of a pharmaceutical composition to a patient, the pharmaceutical composition including an extract of Balanites aegyptiaca, wherein the pharmaceutical composition is capable of treating or reducing symptoms of coronavirus disease. Pharmaceutical compositions of the present disclosure can be used for treating or reducing symptoms of COVID-19.

ULTRAPOTENT BROARDLY NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2 VARIANTS AND METHODS OF USE THEREOF

Resumen de: WO2025140539A1

Provided is in the field of immunology. Provided are broadly neutralizing antibodies against SARS-COV-2 variants, compositions and methods of prevention and treatment of SARS-COV-2 infection or transmission.

PHARMACEUTICAL COMPOSITIONS

Resumen de: US2025213633A1

A method of treating or reducing symptoms of coronavirus disease includes administering a therapeutically effective amount of a pharmaceutical composition to a patient, the pharmaceutical composition including an extract of Balanites aegyptiaca, wherein the pharmaceutical composition is capable of treating or reducing symptoms of coronavirus disease. Pharmaceutical compositions of the present disclosure can be used for treating or reducing symptoms of COVID-19.

POLYNUCLEOTIDE VACCINES AND METHODS OF USING THE SAME

Resumen de: US2025213679A1

Disclosed herein are polynucleotides comprising a first nucleic acid encoding a first pathogen antigen and, optionally, a second nucleic acid encoding a second pathogen antigen, and, optionally, a nucleic acid encoding an immune modifier. In some aspects, the first pathogen antigen is a SARS-CoV-2 spike protein or antigenic fragment thereof. In some aspects, the second pathogen antigen is a SARS-CoV-2 protein or an antigenic fragment thereof. In some aspects, polynucletide includes two or more different immune modifiers. Also disclosed herein are vectors, compositions, pharmaceutical compositions, vaccines, lyophilized compositions, and cells comprising such polynucleotides. Methods of production and therapeutic use are also disclosed herein.

DOSAGE FORMS OF ACTIVE SUBSTANCES USED AGAINST VIRAL DISEASES IN DRY POWDER INHALER DEVICE FOR SYMPTOMS CAUSED BY COVID-19 AND OTHER VIRAL LUNG DISEASES

Resumen de: US2025213469A1

The present invention relates to a pharmaceutical composition in inhalable pre-metered dry powder form that comprises at least one excipient (for example carrier) and at least one active substance used against viral diseases to locally administer it to the lungs for use in the treatment of symptoms of viral lung diseases including COVID-19 caused by Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-COV-2) by means of dry powder inhaler through inhalation. The present invention also relates to methods for preparation of said pharmaceutical composition and the use of these active substances in symptoms caused by COVID-19. similar viral lung diseases, influenza.

Engineered Probiotic Delivery System for Anti-SARS-COV-2 Treatment and Immunity Against Viruses

Resumen de: US2025213666A1

A novel genetically modified bacterium is disclosed. The bacterium has one or more anti-spike glycoprotein nanobodies on the outer membrane of the bacterium. In one embodiment, one or more of the anti-spike glycoprotein nanobodies have been fused with Intimin. In another embodiment, one or more of the anti-spike glycoprotein nanobodies have been fused with Lpp-OmpA.

METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES

Resumen de: US2025213601A1

Provided are methods and compounds for treating (or for use in manufacturing a pharmaceutical dosage form to treat) viral infections by administering avermectin-based bioavailable highly permeable compounds. The compounds, compositions, and methods provided are particularly useful for the treatment of SARS-CoV-2, dengue, chikungunya, yellow fever, Zika and other viral infections.

SARS-CoV-2 SARS-CoV-2 SARS-CoV-2 PEPTIDES NUCLEIC ACIDS RECOMBINANT EXPRESSION VECTORS CELLS VACCINE MATERIALS FOR SARS-COV-2 VACCINE COMPOSITIONS FOR SARS-COV-2 AND METHODS OF IMMUNIZING SARS-COV-2

Resumen de: WO2025135605A1

Disclosed are peptides, nucleic acids, recombinant expression vectors, cells, a SARS-CoV-2 vaccine substance, a SARS-CoV vaccine composition, and a SARS-CoV-2 immunization method.

SARS-COV-2 IMMUNOGENIC COMPOSITIONS AND METHODS

Resumen de: AU2023329395A1

The present disclosure relates to compositions and methods for vaccinating a subject against multiple SARS-CoV-2 variants that involves the making and delivery of extracellular vesicles expressing on their surface engineered spike protein and/or engineered nucleocapsid protein to the subject. The present invention also relates to compositions and methods for the design, preparation, manufacture, formulation, and/or use of spike-display and nucleocapsid-display vesicular vaccines designed to elicit strong humoral and cellular immune responses against multiple SARS-CoV-2 variants.

NASAL SPRAY FOR USE FOR THE TREATMENT OF INFECTIONS WITH SARS-COV-2

Resumen de: PH12022550269A1

Compositions for treatment or prevention of viral infections, such as influenza A and B, coronaviruses, including but not limited to COVID-19, and rhinoviruses, along with related treatment methods. Certain compositions according to preferred embodiments of the invention may comprise chlorpheniramine, xylitol, and other inactive ingredients, such as aloe vera and / or grapefruit seed extract.

-SARS-CoV-2 Pan-SARS-CoV-2 vaccine composition

Resumen de: KR20250099656A

본 발명은 팬-SARS-CoV-2 백신 조성물 및 이의 용도에 관한 것이다. 본 발명의 팬-SARS-CoV-2 항원 및 이를 포함하는 백신 조성물은 다양한 SARS-CoV-2 변이주에 대해 우수한 백신 효능을 나타내는 바, 보다 효과가 향상된 백신을 제조할 수 있다는 장점이 있다.

2-AMINO-N-(4-AMINO-3,4-DIOXO-1-(2-OXOPYRROLIDIN-3-YL)BUTAN-2-YL)BENZAMIDE DERIVATIVES AS PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION

Resumen de: MX2025005933A

The present invention provides a compound of Formula I wherein R₁, R₂, R₃, R₄, R₅, R₆, R₇, and subscripts x and n are as described herein and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for the treatment, inhibition, or amelioration of one or more disease states that could benefit from inhibition of a coronavirus, including SARS-CoV, MERS-CoV and SARS-CoV-2. The compounds of this invention could further be used in combination with other therapeutically effective agents, including but not limited to, other drugs useful for the treatment of coronavirus infection. The invention furthermore relates to processes for preparing compounds of Formula I, and pharmaceutical compositions which comprise compounds of Formula I and pharmaceutically acceptable salts thereof.

USE OF SHENLING BAIZHU IN PREPARING MEDICAMENT FOR TREATING POST-HEALING SEQUELAE OF NOVEL CORONAVIRUS INFECTED PERSON

Resumen de: MX2025007247A

Provided is use of Shenling Baizhu in preparing a medicament for treating post-healing sequelae of a novel coronavirus infected person. The sequela is selected from at least one of short of breath, fatigue and weakness, inappetence, and diarrhea. The Shenling Baizhu is prepared from the following raw materials in parts by weight: 400 parts of ginseng, 400 parts of poria cocos, 400 parts of Rhizoma Atractylodis macrocephalae stir-fried with bran, 400 parts of Chinese yam, 300 parts of fried white hyacinth beans, 200 parts of lotus seeds, 200 parts of coix seeds stir-fried with bran, 200 parts of Fructus amomi, 200 parts of Platycodon grandiflorum, and 400 parts of liquorice.

CRYSTAL FORMS OF AN ANTI-SARS COV-2 AGENT

Resumen de: MX2025003937A

The present invention features crystalline forms of Compound I, including polymorphs and pseudopolymorphs, which are useful in the preparation of pharmaceutical compositions.

ANTIBODIES CAPABLE OF BINDING TO THE SPIKE PROTEIN OF CORONAVIRUS SARS-COV-2

Resumen de: MA61946B1

The disclosure relates to antibodies useful for the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19. In particular, the disclosure relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2 and uses thereof.

SARS-COV-2 SUBUNIT VACCINE

Resumen de: US2024316183A1

The present invention relates to a protein subunit vaccine comprising at least one antigen characterized in that it comprises at least one monomer from at least one variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), wherein the at least one monomer is selected from the group consisting of the S1 subunit of the Spike protein or the receptor-binding domain (RBD) of the Spike protein. In an aspect of the present invention, the protein subunit vaccine comprises at least one antigen characterized in that it comprises two monomers from at least one variant of SARS-CoV-2, wherein each of the monomers are selected from the group consisting of the S1 subunit or RBD protein, and wherein the monomers are chemically bound to each other, optionally through a linker, forming fusion dimers or non-fusion dimers. The protein subunit vaccine may further comprise at least an adjuvant and at least an immunostimulant.

METHODS AND COMPOSITIONS FOR INHIBITING VIRAL METHYLTRANSFERASES

Resumen de: US2025205178A1

SARS-CoV-2 has caused a global pandemic with significant humanity and economic loss since the beginning of 2020. Flaviviruses such as Zika and Dengue viruses are also significant human pathogens. Although SARS-CoV-2 vaccines are effective in preventing severe disease outcomes, they are less effective in controlling infection or re-infection, particularly due to rapid evolution of viral variants of SARS-CoV-2. Currently only limited options are available to treat SARS-CoV-2 and flavivirus infections for vulnerable populations. Potential of a future pandemic of other viruses is high. The present invention features compositions and methods for a universal high throughput screening (HTS) assay to identify inhibitors targeting the S-adenosyl-L-methionine (SAM)-binding site of viral methyltransferases (MTases) using SAM as a methyl donor.

PAN-CHEMOKINE ANTAGONISTS FOR USE IN TREATING CANCER AND IMMUNE DISORDERS

Resumen de: US2025206754A1

A chemical compound 2-({6-phenylthieno2,3-dpyrimidin-4-yl}oxy)benzamide for use as a CCR7 (C-C chemokine receptor type 7) antagonist. It is also a pan-chemokine antagonist and has an antagonistic effect to CCR1, CCR2, CCR3, CCR5, CCR9 and CXCR4 chemokine receptors for use in the prevention of metastatsis formation in lung, liver and ribs in in vivo mice breast cancer model. Also described are chemical compounds 3-chloro-2-{6-(2-chlorophenyl)-2,5-dimethylthieno2,3-dpyrimidin-4-yloxy}benzamide and 3-chloro-2-{6-(2-chlorophenyl)-2-methylthieno2,3-dpyrimidin-4-yloxy}benzamide, as pan-chemokine antagonists. These compounds are for use in the prevention or treatment of: (i) diseases associated with chemokine receiptors which are, specifically, lung, liver, ribs and lymph node metastasis and the progression of many different malignancies such as breast, gastric, skin (melanoma), head and neck, lung, esophageal, hepatocellular, cervical, thyroid, tonsillar, colorectal and prostate cancers; (ii) virus infection diseases associated with chemokine receptors such as HIV-1, HIV-2, SARS-CoV-2 (COVID-19); and (iii) the immune related diseases such as psoriasis, arthritis and atopic demiatitis.

PEPTIDES, NUCLEIC ACIDS, RECOMBINANT EXPRESSION VECTORS, CELLS, SARS-COV-2 VACCINE SUBSTANCE, SARS-COV-2 VACCINE COMPOSITION, AND SARS-COV-2 IMMUNIZATION METHOD

Resumen de: WO2025135605A1

Disclosed are peptides, nucleic acids, recombinant expression vectors, cells, a SARS-CoV-2 vaccine substance, a SARS-CoV vaccine composition, and a SARS-CoV-2 immunization method.

SHORT VIRAL RNAS (SVRNAS) WITH THERAGNOSTIC POTENTIAL IN INFECTION WITH SARS-COV-2 AND RELATED VIRUSES

Resumen de: WO2025137577A1

Provided herein are short viral RNA (svRNA) and human RNA sequences that exhibit modulated expression during viral infection and are therefore useful for detecting viral infections. Further disclosed herein are compositions, methods, and kits for detecting and treating infections, including early-stage and latent infections with low viral titers. In certain embodiments the compositions, methods, and kits for detecting and treating infections include detecting in a sample from a subject 10-50 nucleotide length short viral RNA (svRNA), modulated expression of 10-50 nucleotide length RNA in the subject, or a combination thereof, thereby detecting infection by a virus in the subject.

T CELL-BASED SARS-COV-2 VACCINE

Resumen de: WO2025137448A1

The present disclosure relates to coronavirus vaccines and methods for use thereof.

SARS-COV-2 SUBUNIT VACCINE

Resumen de: US2025186576A1

The present invention relates to a protein subunit vaccine comprising at least one antigen characterized in that it comprises at least one monomer from at least one variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), wherein the at least one monomer is selected from the group consisting of the SI subunit of the Spike protein or the receptor-binding domain (RBD) of the Spike protein. In an aspect of the present invention, the protein subunit vaccine comprises at least one antigen characterized in that it comprises two monomers from at least one variant of SARS-CoV-2, wherein each of the monomers are selected from the group consisting of the S1 subunit or RBD protein, and wherein the monomers are chemically bound to each other, optionally through a linker, forming fusion dimers or non-fusion dimers. The protein subunit vaccine may further comprise at least an adjuvant and at least an immunostimulant.

TREATMENT OF VIRUSES WITH ANTIVIRAL NUCLEOSIDES

Nº publicación: US2025205268A1 26/06/2025

Solicitante:

MERCK SHARP & DOHME LLC [US]
EMORY UNIV [US]
MERCK SHARP & DOHME LLC,
EMORY UNIVERSITY